Skip to content

Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity and gene induction study.

Mikhail Kalinichev, Melanie J Robbins, Elizabeth M Hartfield, Peter R Maycox, Susan H Moore, Kevin M Savage, Nigel E Austin, Declan N C Jones

Progress in neuro-psychopharmacology & biological psychiatry February 15, 2008 DOI: 10.1016/j.pnpbp.2007.09.008 via PubMed

Summary

AI-generated from the abstract

In a rat model of acute psychosis induced by phencyclidine (PCP), the drug's effects on movement and gene expression depend on how it is given. Adult male rats received PCP either injected into the abdomen or under the skin. PCP given under the skin produced stronger and longer-lasting hyperactivity, higher drug levels in blood and brain, and greater activation of several immediate early genes in the prefrontal cortex compared to injection into the abdomen. The differences in drug concentration appeared within 30 minutes and lasted up to 4 hours. The subcutaneous route provides a more robust and consistent model for studying acute psychosis.

Study at a glance

Characteristics Experimental animal study Peer reviewed
Population Adult male rats
Intervention Phencyclidine (PCP)
Dose 1.0-5.0 mg/kg
Duration 60-minute locomotor assessment; pharmacokinetics followed up to 4 hours
Key finding Subcutaneous administration of PCP produces more robust and longer-lasting locomotor hyperactivity, higher drug concentrations in blood and brain, and greater immediate early gene induction than intraperitoneal administration.

Abstract

In a putative model of acute phencyclidine (PCP)-induced psychosis we evaluated effects of the drug on locomotor activity (LMA) and immediate early gene (IEG) induction in the rat using two routes of drug administration, intraperitoneal (i.p.) and subcutaneous (s.c.). Adult male rats received saline or PCP (1.0-5.0 mg/kg) either i.p or s.c. and were assessed for LMA for 60 min. At the end of the LMA testing animals were culled and blood and brain samples were collected for PCP concentration analysis. Separate cohorts of animals received 5.0 mg/kg PCP (i.p. or s.c.) and were used to investigate (1) the pharmacokinetics of PCP or (2) induction of IEG (Arc, c-fos, BDNF, junB, Krox-20, sgk-1, NURR1, fra-2, Krox-24, and egr-3) mRNA expression in the prefrontal cortex (PFC). Administration of PCP resulted in locomotor hyperactivity which was more robust and longer-lasting in animals dosed s.c. compared to i.p.-treated-animals. Differences in hyperlocomotion were paralleled by higher concentrations of PCP in the blood and in the brain of s.c.-treated animals compared to i.p.-treated animals. The differences in the concentration of PCP between the two routes of administration were detected 30 min after dosing and persisted for up to 4 h. Administration of PCP via the s.c. route resulted in induction of more IEGs and consistently larger magnitudes of induction than that via the i.p. route. Therefore, we have outlined the dosing conditions to induce rapid and robust effect of acute PCP on behaviour, gene induction, and pharmacokinetic profile, to allow investigation of this as a potential animal model of acute psychosis.

Comments

No comments yet.

Log in to comment